IDEXX Laboratories Inc. (IDXX) Stock

IDEXX Laboratories Inc. trades at a P/E ratio of 49.01, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 44.05 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 4.39 indicates a premium valuation even accounting for growth.

With a beta of 1.55, IDEXX Laboratories Inc. is significantly more volatile than the market. For every 10% market move, this stock tends to move 15% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 29.50 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

IDEXX Laboratories Inc. achieves a profit margin of 22.80%, meaning it retains $22.80 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 31.70% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 59.30% and ROA at 23.00%, the company generates strong returns on invested capital.

IDEXX Laboratories Inc.'s revenue grew by 3.60% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 5.30% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry averages for proper context.

IDEXX Laboratories Inc. has a market capitalization of $42.73B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 80.42M shares outstanding, the company's ownership is relatively concentrated. As a participant in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry, it competes with other firms in this sector.

IDEXX Laboratories Inc.'s book value per share is $17.93, while the current stock price is $533.37, resulting in a price-to-book (P/B) ratio of 29.75. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

13 analysts cover IDXX with 46% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $507.08 implies -4.9% downside, but targets are often adjusted to follow price moves rather than predict them.

Current analyst recommendations:3 Strong Buy, 3 Buy, 6 Hold, 01 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

RSI data is not available for this stock.

MACD and moving average data are not available for this stock.